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Summary
Background and aims: Prevalence of hepatitis C virus (HCV) in intravenous drug
users (IDU) varies in different areas according to socioeconomic and geographical
circumstances. The present study was performed to determine seroprevalence of
HCV in IDU individuals in Ahvaz, Iran.
Materials and methods: 142 IDU patients were included in this retrospective study
in Ahvaz southwest Iran from 2001 to 2006. Patients were placed in two groups
determined by HCV Ab positive or negative status. Data were analyzed using SPSS
for Windows (version 11.5; SPSS Inc., USA) software.
Results: Out of total 142 cases, 74 persons (52.11%) had a positive HCV-Ab test
according to the ELISA method. There was no difference in age, sex, level of edu-
cation, residency and co-infection with HIV and hepatitis B virus between HCV-Ab
positive (HAP) and HCV-Ab negative (HAN) groups (p > 0.05). HCV-Ab positivity was
signiﬁcantly related to imprisonment and duration spent in prison [OR: 3.22, 95%
(CI) 2.61—3.76, p < 0.0001].
Conclusion: Patients with IDU constitute a high-risk group for acquisition of HCV
infection. Transmission of HCV via sharing syringe and needle as well as blood
transfusion has been a signiﬁcant source of hepatitis C infection for patients with
intravenous drug addiction.
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ntroductionntravenous drug users (IDU) are an increasing pop-
lation in Iran, which presents important health
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roblems [1]. These individuals act as sources of
nfectious pathogens in the community [2]. Accord-
ng to the Iranian welfare organization report,
6.2% of addicted individuals in Iran are IDU of
hom half of them shared needles [3]. Hepati-
is C virus (HCV) infection has spread considerably
mong IDU in parts of Asia. Sharing of injection
quipment and imprisonment are the strongest
Sciences. Published by Elsevier Ltd. All rights reserved.
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predictors of HCV infection in some area of Asia
such as Iran [2,3]. Frequency of HCV infections in
IDU varies in different areas according to socioe-
conomic and geographical factors as well as HIV
infection rate [2,4]. HCV has emerged as a major
cause of chronic liver disease worldwide [5,6]. It
is the most common cause of transfusion-acquired
viral hepatitis [7]. More than 60% of individuals
exposed to HCV develop chronic infection. Approx-
imately 20—30% of chronically infected individuals
will develop liver cirrhosis and/or hepatocellular
carcinoma when followed for 20—30 years [5]. HCV
affects 50—60% of all IDUs globally and thus consti-
tute a potential reservoir of HCV in the community
[8]. Published reports have described viral hepati-
tis as the most common infectious disease in this
population [4—10]. Many studies in Iran document
IDUs with HCV infection rates of between 38% and
47% [11,12].
The present study was performed to determine
incidence of HCV infections in admitted IDU indi-
viduals in Ahvaz a city located in the south west of
Iran.
Materials and methods
This is a retrospective descriptive case series
study which was performed in Ahvaz, the capi-
tal city of Khuzestan province in southwest Iran
from 2001 to 2006. The medical records of 239
IDU patients admitted to every in teaching hospi-
tal afﬁliated with the Jundishapoor University of
Medical Sciences (JUMS) were reviewed. Patients
with HCV-antibody (HCV-Ab) test were included.
Data concerning demographics, residency, impris-
onment, risk factors for HCV (prior surgery, blood
or blood product transfusion and unsafe sexual
contact and sharing of syringes and needles), clin-
ical ﬁndings suggestive of hepatitis and laboratory
data were extracted. Speciﬁcally HCV-Ab and full
liver function tests (including aminotransferase;
ALT, AST) were also recorded. Table 1 shows the
distribution of patients according gender, age, res-
idency, imprisonment, duration of incarceration,
history of surgery, prior blood/blood product trans-
fusion, unsafe sexual contact, co-infection with
HIV or HBV, clinical ﬁndings and laboratory data.
ALT and AST above 40 were deﬁned as abnormal.
Individuals at least two of above mentioned clini-
cal ﬁndings were deﬁned as symptomatic patients.
Patients were placed in two groups: HCV-Ab posi-
tive and HCV-Ab negative and were analyzed using
chi square test and odds ratio in SPSS for Windows
(version 11.5; SPSS Inc., USA) software.
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esults
uring the study period only 142 of 239 IDU patients
ad been tested for presence of HCV-Ab. The mean
ge was 26.3± 5.7 years (range 20—55). A male
redominance was noted, with only 8.4% of the
ample being female. More than 75% had a history
f imprisonment due to addiction and its related
ocial behavior. Mean duration of incarceration
as 3.43± 0.28 years for the seropositive group
nd 2.11± 0.32 years for the seronegative group
p < 0.05). Almost half of the study population was
neducated. 68.9% of the seropositive group and
2.6% of the seronegative group shared in injecting
quipment (p < 0.05). Seventy four persons (52.11%)
ad a positive HCV-Ab test according to the ELISA
ethod, among them less than 25% were symp-
omatic from chronic hepatitis (when deﬁned as
ore than 6 months duration). Nearly a third of
his group had increased ALT and AST with mean of
46.4± 48.12 and 239± 65.6, respectively. There
ere three patients with symptomatic acute hep-
titis in the seronegative group due to hepatitis
, typhoid fever and infective endocarditis. Five
symptomatic cases in this group had increased ALT
nd AST with mean of 296.3± 28.2 and 209± 45.1,
espectively, among them two patients on anti-
uberculosis drugs. As shown in Table 1, there
as no signiﬁcant difference in age, gender, resi-
ency, educational status, co-infection with other
iral pathogens and sexual behavior between the
wo groups (p > 0.05). HCV-Ab positivity was signiﬁ-
antly related to imprisonment and duration spent
n prison [OR: 3.22, 95% (CI) 2.61—3.76, p < 0.0001].
iscussion
n the present study, the prevalence of HCV-Ab
ositivity was 52% similar to other HCV sero-
revalence studies in Iran [8,9,12]. Iranian IDU
atients show HCV prevalence rates between 50%
nd 100% [8]. Reports of HCV infection among IDU
ary between 14.5% and 85% [13—17]. The major-
ty of our patients were chronic carriers of HCV
onsistent with literature [2]. Two cases of seroneg-
tive IDU showed increased ALT and AST due to
nti-tuberculosis drug-induced hepatitis, the rea-
on for elevated ALT and AST in three seronegative
ases was unclear. We believe that recent HCV
nfection or alternative cause of hepatitis must
onsidered even in the setting of high risk IDU pop-
lations. Result of our study showed that the mean
ge in seropositive cases was similar to seronega-
ive cases. Age, gender and level of education of
atients have no predictive value in HCV infection
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Table 1 Distribution of IDU patients according to HCV-Ab results and epidemiological factors, Ahvaz, Iran.
Variables HCV-Ab positive, N (%) HCV-Ab negative, N (%) p value
Age (years) 25.7± 5.2 26.9± 5.7 0.70
Gender
Male 70 (94.6) 60 (88.2) 0.23
Female 4 (5.4) 8 (11.8)
Education status
None 44 (59.5) 31 (45.6) 0.12
Primary 23 (31.1) 21 (30.9) 1.00
Secondary 7 (9.4) 13 (19.1) 0.14
High education 0 (0.0) 3 (4.4) 0.10
Residency
Rural 11 (14.9) 19 (27.9)
Urban 63 (85.1) 49 (72.1) 0.09
Imprisonment 67 (90.5) 41 (60.3) <0.0001
Duration of prison
<2 years 9 (12.2) 22 (32.3)
2—5 years 54 (72.9) 11 (16.2) <0.0001
>5 years 4 (5.4) 8 (11.8)
HIV co-infection 12 (16.2) 6 (8.8) 0.21
HBV co-infection 3 (4.1) 1 (1.5) 0.62
Unsafe sexual contact 47 (63.5) 38 (55.8) 0.39
Symptomatic hepatitis 18 (24.3) 3 (4.4) 0.0007
Abnormal transaminase 24 (32.4) 5 (7.3) 0.0002
History of surgery 13 (17.6) 4 (5.9) 0.03
Blood/blood transfusion 21 (28.4) 4 (5.9) 0.0003
Total 74 (100) 68 (100)
HCV: hepatitis C virus; Ab: antibody; HIV: human immunodeﬁciency virus; HBV: hepatitis B virus; IDU: injecting drug users. p
value <0.05 is considered signiﬁcant. High education: university education; symptomatic hepatitis: patients with at least two
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Hsign or symptoms (e.g. icterus, abdominal pain, anorexia, dark
aminoteransferase level more than 40.
nd it is similar to other studies performed before
n Iran and other countries [12,18,19]. Although the
ate of unedcuated among the general population
n Ahvaz is similar to other parts of Iran, this popu-
ation rises markedly among the IDU sample. In our
tudy there was no signiﬁcant relation between sex-
al activity, co-infection with HIV and HBV in posi-
ive and negative anti-HCV Ab group’s. This ﬁnding
s not consistent with previous reports [20—22].
he present study, like other studies [12,20—22]
evealed that HCV seropositivity was signiﬁcantly
ssociated with imprisonment and longer duration
f incarceration. Possible theory for this data is:
he majority of prisoners who are new are there
ecause of IDU related offenses and therefore most
risoners are IDUs. In our investigation we studied
ome risk factors related to HCV. IDU individuals
ho had spent more time in prison and those who
ad a prior history of surgery and blood transfusion
ere signiﬁcantly more likely to be positive for anti-
odies to HCV. Being in prison in Iran may emerge be
n independent risk factor for hepatitis C infection.
i
b
o
p, malaise and hepatomegaly); abnormal transaminase: serum
e found no statistical association between HCV
nd other factors such as residency in rural or urban
rea. The rates of co-infection of HCV, HBV and HIV
n our patients were considerably lower than those
bserved in other studies, including those in devel-
ping countries [20—22]. Baseline HIV rates in this
tudy were lower than the rate reported previously
4]. This difference may be due to the small sample
ize of the study. Because of limited available data
n Iran about this subject further comparison was
ot possible. There were some limitations in our
tudy. As with any retrospective study, the study
opulation may not be a representative of all Ira-
ian IDU, rather a selected population who needed
npatient admission, perhaps identifying only those
ith more severe disease. In addition, because of
ifferent causes of admission in different hospitals,
CV-Ab test was not routinely performed for all IDU
ndividuals on arrival. Since HCV infection is deﬁned
y HCV-RNA positivity and not on mere presence
f antibody, HCV-Ab can only reﬂect on sero-
revalence of HCV. Due to religious beliefs, many
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individuals withheld comprehensive responses to
questions concerning sexual behavior. Therefore,
the ﬁndings concerning HCV-Ab positivity and sex-
ual contact should be considered with caution. The
high chance of HCV infection from sharing in injec-
tion equipment and following transfusion of blood
warrants a renewed emphasis on harm reduction
strategies and careful pre-transfusion screening of
blood for anti-HCV by all blood banks. According to
the high proportion of our patients with history of
prior or ongoing imprisonment, and the potential
inﬂuence of prison on the spread of HCV infec-
tion throughout the community, more consideration
most be paid to surveillance of HCV infection in all
Iranian prisons.
Conclusion
Patients with IDU constitute a high-risk group for
acquisition of HCV infection. Transmission of HCV
via sharing syringe and needle as well as blood
transfusion has been a signiﬁcant source of hep-
atitis C infection for patients with injecting drug
addiction. Rapid diagnosis of this infection and
appropriate management can contain infection in
community.
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